The quest to deliver optimal radiation therapy for patients with prostate cancer has led to a variety of advances in technologies and techniques, yet key questions remain unanswered.

Challenges remain regarding the mechanisms of docetaxel resistance, whether combination studies continue to make sense, and how the sequencing of docetaxel may impact toxicity and efficacy.

A new study suggests that germline mutations of BRCA1/2 could play a significant role in more-aggressive cases of prostate cancer. Additionally, BRCA2 mutations were specifically linked to poor overall survival.